The Wallenberg Centre for Molecular Medicine Lund was established, as one of four centres in Sweden, in 2015 through a collaboration between the Knut and Alice Wallenberg Foundation (KAW), Lund University (LU), and Region Skåne. The initiative originated from KAW, which is also the primary funder of the centre. The centres received initial funding of over SEK 800 million for the first 10-year period (2015–2024), with an additional SEK 240 million allocated for the period 2025–2028.
The centres are part of a long-term national initiative by KAW aimed at re-establishing Sweden as a leading Life Science nation. The goal is to create the best possible conditions for world-leading molecular and translational research, and to build knowledge and competence among the next generation of leaders in academia and the healthcare sector.
By recruiting young group leaders and offering them generous start-up packages, strong conditions are created for their professional development, the establishment of independent research groups, and the long-term, strategic development of their own lines of research.
This year, WCMM Lund proudly commemorates a decade of pioneering research in molecular and translational medicine. This will be celebrated with conference
Anniversary Conference: “Translating Basic Science into Clinical Breakthroughs”
To mark this milestone, WCMM Lund is hosting a full-day anniversary conference:
- Date & Time: 18 September 2025, 09:00–17:00
- Venue: Universitetshuset, Lund
- Theme: Celebrating a decade of excellence in bridging lab insights with healthcare impact
Keynote Line‑up
- Prof. Michel Sadelain (Columbia University) – A pioneering force in CAR‑T cell therapy, known for his team’s breakthroughs targeting CD19 since 2007 and eventual FDA approvals
- Prof. Rolf Berger (University of Groningen) – Expert in pediatric cardiology and pulmonary vascular disease, with contributions to care centralisation and basic–clinical synergy
- Prof. Lotte Bjerre Knudsen (Novo Nordisk) – Renowned for driving the development of GLP‑1 agonists like liraglutide and semaglutide, transforming diabetes and obesity treatments
The celebration will reflect on 10 years of innovation, collaboration, and scientific excellence—and cast a visionary eye toward the future.
For the full program & registration: WCMM Event